Objective-Inflammation plays a critical role in the development of abdominal aortic aneurysms (AAAs). Because stromal cell-derived factor 1 (SDF-1) is known for its ability to attract inflammatory cells, we investigated whether SDF-1/ chemokine (C-X-C motif) receptor 4 (CXCR4) axis is expressed in aneurysmal aortic wall and plays a role in AAA physiopathology and asked whether its blockade modulates AAA formation and expansion. Approach and Results-Quantitative real-time polymerase chain reaction analysis showed that SDF-1α and CXCR4 mRNA levels are increased in both human and CaCl 2 -induced mouse AAA wall and are positively correlated to the aortic diameter in mice. ELISA quantification and immunostaining demonstrated that, in mice, aortic SDF-1α is rapidly induced during AAA formation, first by apoptotic vascular smooth muscle cells in the injured media and then by adventitial macrophages once AAA is fully established. Using green fluorescent protein-positive (GFP +/− ) bone marrow transplantation experiments, we demonstrated that aortic SDF-1 overexpression is implicated in the recruitment of bone marrow-derived macrophages within the AAA wall. Furthermore, in mice, blockade of CXCR4 by AMD3100 decreases the infiltration of adventitial macrophages, inhibits AAA formation, and prevents aortic wall destruction. AMD3100 reduces the mRNA levels of MMP-12 and MMP-14 as well as that of inflammatory effectors MCP-1, MIP-1β, MIP-2α, RANTES, IL-1β, IL-6, TNF-α, and E-selectin. Finally, AMD3100 stabilizes the diameter of formed, expanding AAAs in 2 experimental models.
A bdominal aortic aneurysms (AAAs) are progressive enlargements of the infrarenal aortas that affect ≈5% of men aged >65 years and spontaneously evolve toward rupture. 1 Currently, the management of AAAs relies on open or endovascular surgery when the aortic diameter reaches 5.5 cm. Although noninvasive echography readily enables the screening of small asymptomatic AAAs, no medical therapies are currently available to alter the natural history of small AAAs. Therefore, understanding the initial steps responsible for aneurysmal degeneration and expansion would help in designing new therapeutic options for the third cause of cardiovascular death.
AAA degeneration involves the destruction of fibrillar extracellular matrix proteins and the depletion of medial vascular smooth muscle cells (VSMCs), leading to the weakening of the aortic wall and dilatation of the aorta. 2 In this destructive process, the recruitment of inflammatory cells in the adventitia and outer media seems to be an initial and determinant step.
Indeed, inflammatory cells, primarily lymphocytes, macrophages, and plasma cells, release proinflammatory mediators and matrix-degrading enzymes (such as matrix metalloproteinases [MMPs] ) and generate elastin degradation peptides that promote immune response and accelerate chronic transmural inflammation. Studies in human AAA tissue reveal a strong correlation between degradation of elastin fibers and the extent of inflammatory infiltrates in the outer aortic wall. 3 The stimulus for the early recruitment of inflammatory cells in AAAs is still uncertain. One plausible mechanism involves the action of chemoattractant cytokines, which regulate leukocyte trafficking. Among them, the stromal cell-derived factor (SDF)-1, also known as chemokine (C-X-C motif) ligand 12 (CXCL12), is known to mobilize hematopoietic progenitor cells and leukocytes from bone marrow (BM) into circulating blood and, subsequently, into peripheral tissues through interaction with its cognate receptor chemokine (C-X-C motif) receptor 4 (CXCR4). 4 ,5 SDF-1 is highly induced in inflamed tissues, where it attracts activated CXCR4 + T cells and monocytes, thereby enhancing local inflammatory responses. In this regard, SDF-1 or its receptors CXCR4 have been associated with chronic inflammatory disease pathogenesis, including rheumatoid arthritis, 6 lupus, 7 allergic airway disease, 8 asthma, 9 and inflammatory bowel diseases. 10 This concept has prompted a pharmacological approach, using the selective blockade of CXCR4 by AMD3100 to curb inflammation and its consequences in animal models of inflammatory disorders. 6, 11, 12 Few study have addressed the role of SDF-1 in aortic aneurysms. Plasma SDF-1α levels have been shown to be positively correlated to the size of ascending aortic aneurysms. 13 Ocaña et al 14 have demonstrated that infiltrating B and T lymphocytes isolated from human AAA walls expressed high level of CXCR4 and that the level of SDF-1α is increased in the adventitia of human AAA wall, suggesting a proinflammatory action of the SDF-1/CXCR4 axis in AAA pathogenesis. But, to date, the effect of SDF-1/CXCR4 axis on the early migration of inflammatory cells within the aortic wall remains unexplored. In the present study, we investigated the aortic expression of SDF-1 (SDF-1α, β, γ) and CXCR4 in human samples and during AAA development in the mouse calcium chloride model. We further evaluated the functional role of the SDF-1/CXCR4 pathway in the recruitment of inflammatory cells within the aortic wall in vivo and the effect of the chronic blockade of CXCR4 by AMD3100 on AAA formation and expansion in 2 experimental models.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

SDF-1/CXCR4 Axis Is Upregulated in Human and Experimental AAAs
We first evaluated whether the expression of the isoforms of SDF-1 and their receptors, CXCR4 and CXCR7, were modulated in the aortic wall of human AAAs ( Figure 1A ). Quantitative real-time polymerase chain reaction analysis showed a marked increase in SDF-1α mRNA in both medial and adventitial layers of human AAAs, when compared with healthy aortas. The expression of SDF-1β mRNA increased only in the medial layer of human AAAs, whereas the levels of SDF-1γ remained unchanged. In parallel with the increased expression of SDF-1α, the levels of CXCR4 mRNA were upregulated in both medial and adventitial layer of human AAAs but those of CXCR7 were unaffected by the pathology.
We then evaluated the time-course of aortic SDF-1, CXCR4, and CXCR7 mRNA expression during AAA development in mice ( Figure 1B-1D ). When compared with NaCl-treated mice, perivascular application of CaCl 2 to the infrarenal abdominal aorta induced a significant increase of the external aortic diameter from day 2 to day 14 after surgery, with a maximum dilatation reaching 150±19% at day 14 ( Figure 1B ), in accordance with previous data. 15 The level of SDF-1α, β, γ, and CXCR4 mRNA increased significantly in mouse aortas after CaCl 2 aneurysmal induction, as early as day 2 and up to day 14 ( Figure 1C) . A positive correlation between aortic mRNA content and aortic diameter was only demonstrated for the SDF-1a isoform and CXCR4 transcripts ( Figure 1D ). As observed in human samples, the level of CXCR7 mRNA was unaffected by the presence of an aneurysm in mice ( Figure 1C) .
Using an ELISA test that specifically detects mouse SDF-1α, we showed that, whereas the aortic level of SDF-1α protein did not change overtime in NaCl-treated mice, its expression increased significantly after periaortic CaCl 2 application, reaching a maximum at day 2 and remaining at this level up to 14 days ( Figure 2A ). As observed for the transcripts, the aortic level of SDF-1α protein was positively correlated to the external aortic diameter (correlation coefficient, 0.837; P<0.0001; Figure 2B ).
Using immunostaining experiments, we showed that, 2 days after CaCl 2 aneurysm induction, SDF-1α is mostly expressed in the injured media, particularly in the region of elastic network destruction where it colocalized with apoptotic α-smooth muscle actin-positive VSMCs ( Figure 2C ). In contrast, 14 days after CaCl 2 aneurysm induction, SDF-1α accumulated exclusively in the adventitial layer of the AAA wall ( Figure 2D ). At this later stage, SDF-1α expression colocalized exclusively with adventitial F4/80+ macrophages and not with α-smooth muscle actin-positive medial VSMCs ( Figure 2D) . Altogether, these observations demonstrated that SDF-1α is rapidly expressed during experimental AAA formation, first by apoptotic VSMCs in the injured media and then by recruited macrophages in the adventitia once AAA is fully established.
SDF-1/CXCR4 Pathway Specifically Recruits Macrophages in AAA Lesions
We then assessed whether the SDF-1/CXCR4 axis may determine recruitment of bone marrow (BM)-derived circulating cells within AAA wall, using a green fluorescent protein-positive (GFP +/− ) BM transplantation approach. In wild-type mice irradiated and rescued with BM cells from GFP +/− syngenic mice, the fraction of fluorescent peripheral blood leukocytes 3 weeks after BM transplantation was 89±8%. At this delay, AAAs were generated in GFP +/− BM transplantation mice by periaortic CaCl 2 application and mice were treated or not with AMD3100, a potent CXCR4 antagonist. Fourteen days later, few BM-derived GFP-positive cells were detectable in the aortic walls of nonoperated or NaCl-treated mice. In contrast, the number of GFP-positive cells present in the aortic wall significantly increased after CaCl 2 application ( Figure 3A and 3B) and where almost exclusively confined to the adventitial layer of AAAs ( Figure 3A ). Chronic treatment with AMD3100 induced a marked mobilization of BM-derived cells, notably polymorphonuclear neutrophils and monocytes in the blood of both NaCl and CaCl 2 -treated mice ( Figure I in the online-only Data Supplement), demonstrating the efficacy of the in vivo Figure 3C ). This result is in accordance with the observation that the infiltration of mac-3+ macrophages within the aneurysmal lesion, 14 days after CaCl 2 application, was reduced by AMD3100 treatment ( Figure 3D ). On the opposite, AMD3100 treatment did not affect the number of T and B lymphocytes recruited within the CaCl 2 -injured aortic wall in mice (57±32 versus 70±42 CD3+ T cells and 24±7 versus 42±15 CD20+ B cells per mm 2 in AMD3100-treated and vehicle-treated AAAs, respectively; both P=NS; n=6-8). To test whether AMD3100 directly affects the recruitment/migration of macrophage precursors, we performed in vitro experiments using human U937 monocytic cells. We demonstrated that SDF-1α strongly increased U937 cells chemoattraction and that pretreatment of U937 cells with AMD3100 abolished their migration toward SDF-1α (fold increase in cell migration induced by SDF-1 when compared with serum-free medium: 1.5±0.3 versus 17.1±1.5 for cells treated or not with AMD3100, respectively; P<0.001; n=4). Altogether, our data demonstrate that during AAA development, SDF-1/CXCR4 signaling specifically stimulates the recruitment/migration of macrophages, not lymphocytes within the AAA wall.
Blockade of CXCR4 by AMD3100 Inhibits AAA Formation in Mice
In human AAAs, destruction of extracellular matrix components is triggered by inflammation and proteolysis. 2, 16 Because blockade of SDF-1α/CXCR4 axis specifically decreased macrophage infiltration after CaCl 2 aneurysmal induction, we tested whether AMD3100 reduces AAA formation in mice. As expected, periaortic CaCl 2 application (n=23) generated an aortic aneurysm after 14 days (79±8% increase in the aortic diameter) when compared with nonoperated aortas (n=10; Figure 4A and 4B). Of interest, chronic blockade of CXCR4 by AMD3100 (n=23) significantly reduced the CaCl 2 -induced In this mouse model, as in human AAAs, aortic dilatation is characterized by the thinning of the aortic wall with destruction of the aortic elastin network ( Figure 4C ) and rarefaction of α-smooth muscle actin-positive VSMCs within the media ( Figure 4D ). Chronic treatment with AMD3100 preserved the medial aortic elastic lamellae ( Figure 4C ) and VSMC contents ( Figure 4D ) in CaCl 2 -treated mice. Stromal cell-derived factor 1 (SDF-1) is rapidly expressed in the aortic wall during abdominal aortic aneurysm (AAA) formation in mice, first by injured vascular smooth muscle cells (VSMCs) and then sustainably by adventitial macrophages. A, SDF-1α protein level in the aortic wall during AAA formation was quantified by ELISA over time and reported to the total protein content. Time course expression of SDF-1α protein on aortic extracts from NaCl-treated (white columns) or CaCl 2 -treated mice (black columns) is shown (n=4-6 per time point in each group); *P<0.01 vs corresponding NaCl-treated group; #P<0.001 vs corresponding group at day 0. B, Correlation between aortic SDF-1α protein expression level and aortic external diameter, 14 days after AAA generation (n=23). r, correlation coefficient. C, Representative images of triple immunofluorescence for elastin (green), α-smooth muscle actin (SMA)-positive VSMCs (red), and SDF-1 or cleaved-caspase 3 (cl-casp3; yellow, top and bottom, respectively) performed on aortic cross section from CaCl 2 -treated mice at day 2 (D2). D, Representative images of triple immunofluorescence for elastin (green), SDF-1 (yellow), and αSMA+VSMCs or F4/80+ macrophages (red, top and bottom, respectively) performed on aortic cross section from CaCl 2 -treated mice at day 14 (D14). 
Blockade of CXCR4 by AMD3100 Decreases the Expression of Inflammatory and Proteolytic Mediators
After 14 days, periaortic CaCl 2 application resulted in an increased expression of all tested inflammatory mediators ( Figure 5 ). Chronic treatment with AMD3100 inhibited the CaCl 2 -mediated increase in MIP-2α, RANTES, IL-1β, TNF-α, inducible nitric oxide synthase (iNOS), and E-selectin mRNA ( Figure 5A ). Despite a trend toward a reduction in MCP-1, MIP-1α, MIP-1β, and IL-6 gene induction in the AMD3100-treated group, changes did not reach statistical significance ( Figure 5A ).
Regarding proteolysis, we showed that mRNA levels of MMP-12, 14, and urokinase-type plasminogen activator (uPA) and their endogenous inhibitor, TIMP-1, increased at day 14 in the AAA wall of CaCl 2 -treated mice and that AMD3100 treatment significantly reduced MMP-12 expression and tended to reduce MMP-14, TIMP-1, and uPA expression ( Figure 5B ). Plasminogen activator inhibitor-1 (PAI-1) mRNA decreased after CaCl 2 -treatment, but AMD3100 had no effect on its expression level. Finally, there was no induction of tPA nor MMP-9 and TIMP-2 transcripts after CaCl 2 application or any effect of AMD3100 treatment (data not shown).
Blockade of CXCR4 by AMD3100 Stabilizes Already-Formed AAAs in Mice and Rats
We then addressed whether chronic CXCR4 blockade would stop further expansion of formed AAAs. For this purpose, we used the CaCl 2 model in mice and alternately used the xenograft model in rats that offers the advantage to mimic important features of human AAAs, including constant expansion, the presence of inflammatory and proteolytic burden, and intraluminal thrombus. 17, 18 In the mouse CaCl 2 model, chronic AMD3100 administration starting 4 days after CaCl 2 application (ie, on established AAAs; Figure 1B ) significantly inhibited aortic diameter expansion on the long term (external aortic diameter at D14, 0.82±0.05 versus 1.09±0.10 mm in AMD3100-treated (n=9) and vehicle-treated (n=8) CaCl 2 mice, respectively; P<0.05; Figure II in the onlineonly Data Supplement). In rats, 14 days after xenograft implantation (D14; ie, at the time of treatment initiation), we showed that the external diameter of abdominal aortas had significantly increased by 109% and was not significantly different between randomized vehicle-treated (n=12) and AMD3100-treated (n=9) rats (external aortic diameter, 2.9±0.2 versus 3.2±0.2 mm; respectively; P=NS). Although AAA diameter continued to expand in vehicle-treated rats, AMD3100 treatment starting at day 14 suspended AAA expansion up to 28 days after treatment initiation (aortic diameter increase at D14+28, −3.7±4.5 versus 16.1±4.7% in AMD3100-and vehicle-treated rats, respectively; P<0.01; Figure 6A and 6B). In rats, the stabilizing effect of AMD3100 was associated with the inhibition of macrophage infiltration within the AAA wall ( Figure 6C ), whereas the aortic recruitment of T-lymphocytes remained unaffected (604±101 versus 559±62 T cell receptorpositive T-cells per mm 2 in AMD3100-and vehicle-treated rats, respectively; P=NS; n=9-10). Hence, after AMD3100 treatment, the reduction of macrophage accumulation in rat AAA walls coincided with the parallel significant decrease in the number of adventitial isolectin B4+ neovessels at day 28 ( Figure 6D ).
Discussion
We show that SDF-1α isoform and its receptor CXCR4 are upregulated in both mice and human AAA wall. SDF-1α is rapidly induced during AAA formation in mice, first by apoptotic VSMCs in the injured media and then in the adventitia where it colocalizes with macrophages. We demonstrate that SDF-1α is implicated in the recruitment of BM-derived inflammatory cells. Furthermore, the blockade of CXCR4 by AMD3100 decreases the infiltration of adventitial macrophages within the AAA wall, inhibits AAA formation, and prevents aortic wall destruction probably by reducing the release of proteolytic and inflammatory effectors. Finally, using a rat model of AAAs, we demonstrate that AMD3100 stabilizes expanding formed AAAs in rats. Our study is the first to focus on differential expression of the 3 major SDF-1 splicing variants, SDF-1α, β, and γ and their 2 specific receptors, CXCR4 and CXCR7. Studying the whole chemokine axis is of particular interest because of the differences in pharmacological and biochemical properties of the different isoforms 14 and because CXCR7 modulates SDF-1/CXCR4 signaling. 19 We show that SDF-1γ level is unaffected in human AAAs. Both SDF-1α and β expressions are increased in human and mouse AAAs. However, if more investigations would be needed to address the specific role of each isoforms in AAA, our finding that SDF-1α is ≈10-fold more expressed than SDF-1β and that CXCR4, but not CXCR7, is strongly induced in both human and experimental lesions points out the importance of the SDF-1α/CXCR4 axis in AAA pathogenesis. In support of this view, we also demonstrate that SDF-1α and CXCR4 mRNA levels, as well as SDF-1α protein level, positively correlate with the aortic diameter in the mouse CaCl 2 model. This result is in accordance with a previous report showing a positive correlation between plasma level of SDF-1α and aortic diameter in ascending aortic aneurysm. 13 SDF-1α is a chemotactic cytokine known to attract inflammatory cells (ie, lymphocytes, monocytes, macrophages, and mast cells), as demonstrated in vitro using chemotaxis assays or in vivo during wound-healing or inflammatory diseases. 20 We have explored the functional and pathological implications of SDF-1α in AAAs. Using a BM transplantation approach, we demonstrate that increased aortic expression of SDF-1α paralleled the recruitment of BM-derived inflammatory cells in the injured aorta in mice. Moreover, blockade of SDF-1α signaling using AMD3100 specifically decreases macrophage infiltration within AAA adventitia without affecting lymphocyte trafficking and reduces aortic destruction. In parallel, AMD3100 limits AAA formation and curbs diameter progression of formed AAAs in mouse and rat models. These results clearly implicate the SDF-1/CXCR4 pathway in the pathogenesis of aneurysmal disease. To gain further mechanistic insight on the role of SDF-1α in AAA pathogenesis, we explore which cellular compartments are involved in the increased aortic expression of SDF-1α in AAAs. We show that, at the onset of AAA formation, SDF-1α is mainly secreted by apoptotic VSMCs present in the injured media, suggesting that VSMC-derived SDF-1α has a role in initiating macrophage recruitment and AAA development. In contrast, later on, aortic SDF-1α expression is exclusively relayed by infiltrated macrophages themselves that may amplify selfrecruitment and exacerbate local inflammation once AAA is fully established. This result is in accordance with recent data demonstrating that in human AAA samples, SDF-1α expression is confined to the vicinity of inflammatory cell infiltrates.
14 Altogether, our data clearly implicate the SDF-1/ CXCR4 pathway in the formation and expansion of AAAs, through the accumulation of macrophages, and not lymphocytes within the AAA wall.
In human and experimental models, infiltration of inflammatory cells into the injured aortic wall plays a key role in orchestrating AAA expansion. 2, 16 Once recruited, inflammatory cells exacerbate local inflammation through the secretion of proinflammatory mediators.
2 Among these inflammatory effectors, monocyte chemotactic protein-1, 21 regulated on activation, normal T-cell expressed and secreted (RANTES), 22 interleukin-1β, 23 interleukin-6, 24 or tumor necrosis factor-α 25 have been clearly implicated in the development of experimental AAAs and are upregulated in human AAA walls. 26 In our study, we show that MCP-1, MIP-1β, MIP-2α, and RANTES mainly produced by macrophages, as well as IL-1β, IL-6, and TNF-α, are overexpressed in the wall of CaCl 2 -induced AAAs. Interestingly, CXCR4 blockade by AMD3100
abrogates the increase of all tested proinflammatory mediators. Besides, E-selectin expression, an adhesion molecule that facilitates the recruitment of inflammatory cells within injured tissues, 27 was also reduced in AMD3100-treated aortas. Our data suggest that SDF-1α/CXCR4 axis governs a loop of self-amplification of the inflammatory process that can be interrupted by a pharmacological approach.
Destruction of the aortic extracellular matrix components and induction of VSMC apoptosis in human AAAs are triggered by MMP-dependent proteolysis 28 and by oxidative stress. 29 In our study, there was no induction of MMP-9 transcripts 14 days after CaCl 2 application, whereas MMP-12 and MMP-14 and iNOS transcripts were upregulated. Chronic AMD3100 treatment inhibited the aortic increase in MMP-12 and MMP-14 as well as iNOS mRNA levels. In human AAAs, iNOS is a major source of reactive oxygen species that are known to increase aortic MMP expression and activation. 30 In AAAs, the extent of MMP release is spatially linked to the development of neovessels in the adventitia/media, 31 and increased adventitial neovascularisation is associated with AAA degeneration or rupture. 31, 32 Our present data show that AMD3100 treatment decreased adventitial angiogenesis in established rat AAAs. Altogether, our data suggest that the inhibition of the aortic destruction by AMD3100 results, at least in part, from a decreased generation of MMPs and reactive oxygen species into AAA wall together with a reduction of macrophage infiltration and adventitial angiogenesis. As a marker of a decrease in inflammatory, proteolytic, and oxidative stress burdens, elastin network and VSMC content were preserved in the residual aortic wall of AMD3100-treated mice.
In humans, current treatments of AAAs rely on elective surgery of large aneurysms (ie, replacement [prosthesis] or strengthening [stentgraft] of the aorta), when the rupture risk balances that of surgery. In fact, these 2 surgical techniques are associated with a high postoperative mortality rate and a limited durability, respectively. Alternative strategies aimed at controlling further expansion of AAAs before surgical threshold are needed. Pharmacological approaches able to stop small AAA expansion would lower the need for surgery and allow for AAA detection by echography in targeted populations.
The average delay between small AAA diagnosis and elective surgery frequently lasts more than 5 years. 34 Over the past decade, our laboratory has promoted cell [35] [36] [37] or gene 38 therapy to stop further AAA expansion, but these 2 approaches are hampered by technical difficulties and potential high cost for a frequent disease. To this regard, 1 major result of our study is that the blockade of CXCR4 by AMD3100 limits AAA formation in mice but also stabilizes already-formed AAAs in 2 experimental models. In humans, short-term AMD3100 delivery is approved by the Food and Drug Administration for mobilizing hematopoietic stem stems from BM to blood for transplantation in cancer. 39 A recent report has shown preliminary evidence for the safety and clinical efficacy of long-term AMD3100 treatment in immunodeficient patients, 40 arguing for a promising interest of AMD3100 as a pharmacological agent to stabilize small AAAs in humans.
Hence, in addition to its effect on inflammation, proteolysis, and oxidative stress, the impact of AMD3100 on AAA growth may be potentiated by its strong mobilizing properties for BM CXCR4 + precursors, notably endothelial progenitors and mesenchymal stem cells, 41, 42 and thereby may promote AAA repair. We have previously shown that increasing endothelial progenitors 36 and mesenchymal stem cells 37 by local cell therapy is able to slow the progression of experimental AAAs. In our study, we did not address whether CXCR4 + cell levels were increased into the peripheral blood after chronic AMD treatment. However, AMD3100 was able to mobilize BM-derived circulating cells and may have facilitated the release and homing of others putative BM-derived CXCR4 + vascular progenitors.
As a conclusion, we have demonstrated that SDF-1α and its receptor CXCR4 are induced in AAA walls in human and mice and that their expression level correlates positively with the aortic diameter in mice. We also showed that AMD3100 inhibits AAA formation and prevents aortic wall destruction in mice and slows the progression of established AAAs in mice and rats, by decreasing inflammation, adventitial angiogenesis, proteolysis, and oxidative stress. We propose that SDF-1/ CXCR4 axis blockade has a great potential as a pharmacological therapy to reduce further expansion of small AAAs. 
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